Építés alatt – nem éles oldal
Belépés
Leállítva1. fázis

A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

A legfontosabb adatok

Ki végzi
Exelixis
Hol
Austin, Denver, Houston, Huntersville, Jefferson, Nashville, New Haven, New York és Washington D.C. (Egyesült Államok)Mind a 10 helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
1. fázis
Résztvevők
9 fő vett részt
Kezdés
2024. okt. 17.
Befejezés
2025. máj. 7.
A vizsgálat típusa
Beavatkozással járó, 3 csoport
A vizsgált kezelések
  • XL495
  • ADC cytotoxic agents
A regiszteradat frissítve
2025. június 25.
Miért állt le
Company Decision

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • For All Participants; Have received at least one standard therapy unless it does not exist, or available therapies are intolerable or no longer effective; For participants, who qualify for approved molecularly selected therapies such as RAS inhibitors, they must have progressed on, relapsed from, been intolerant to, ineligible, or refused those therapies
  • Expansion Stage; Diagnosis of metastatic advanced UC (primary tumor: renal pelvis, ureter, urinary bladder, or urethra); At least one measurable lesion as defined by RECIST, version 1.1; Participants must be eligible for sacituzumab govitecan treatment as their next line of therapy
  • At least one but no more than 3 prior lines of therapy
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (0-2 for monotherapy; 0-1 for combo)

Ki nem vehet részt

  • Prior anticancer treatment, including:; Radiation therapy within 2 weeks before first dose of study treatment
  • Diagnosis of another cancer within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with standard therapy
  • Known brain metastases or cranial epidural disease
  • Current or recent severe illness
  • Known history or positive test for human immunodeficiency virus (HIV) unless meets specific criteria
  • Active infection with hepatitis B virus or hepatitis C virus
  • Malabsorption syndrome
  • History of solid organ, autologous or allogenic stem cell transplant
  • Active autoimmune disease with skin involvement

Helyszínek itt: Egyesült Államok

  • Austin, TexasHospital not named in the registry
  • Denver, ColoradoHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Huntersville, North CarolinaHospital not named in the registry
  • Jefferson, LouisianaHospital not named in the registry
  • Nashville, TennesseeHospital not named in the registry
  • Nashville, TennesseeHospital not named in the registry
  • New Haven, ConnecticutHospital not named in the registry
  • New YorkHospital not named in the registry
  • Washington D.C., District of ColumbiaHospital not named in the registry

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this study is to obtain safety, tolerability, PK, and preliminary clinical antitumor activity for XL495 as a single agent and in combination with select cytotoxic agents in participants with locally advanced or metastatic tumors for whom life-prolonging therapies do not exist or available therapies are intolerable/no longer effective.

A vizsgálat 3 csoportja

  • Dose Escalation XL495A vizsgált kezelés

    Group(s) of participants with advanced metastatic tumors who will receive increasing doses of XL495.

    Kezelés: XL495

  • Dose Finding XL495 + ADC cytotoxic agentsA vizsgált kezelés

    Group(s) of participants with advanced metastatic tumors who will receive XL495 and Antibody drug conjugate (ADC) cytotoxic agents together at increasing doses.

    Kezelés: XL495 és ADC cytotoxic agents

  • Expansion XL495 + ADC cytotoxic agentsA vizsgált kezelés

    Group(s) of participants with urothelial cancer who will receive XL495 and ADC cytotoxic agents at the recommended dosage(s) of expansion (RDE \[s\]) determined during the dose-escalation and dose-finding stages.

    Kezelés: XL495 és ADC cytotoxic agents

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Dose-escalation, Dose-finding, and Expansion Study of XL495 as a Single Agent and in Combination Therapy in Participants With Locally Advanced or Metastatic Solid Tumors
A regiszteradat frissítve
2025. június 25.